VCH-916
Code | Size | Price |
---|
TAR-TQ0122-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-TQ0122-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
VCH-916 is a new nonnucleoside inhibitor of HCV NS5B polymerase.
CAS:
1200133-34-1
Formula:
C26H36KNO4S
Molecular Weight:
497.74
Pathway:
Microbiology/Virology; Proteases/Proteasome
Purity:
0.98
SMILES:
[K+].COC1CCC(CC1)N(C(=O)C1CCC(C)CC1)c1cc(sc1C([O-])=O)C1=CCCCC1
Target:
HCV Protease
References
Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164
Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161.
Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703